Short-term treatments for acute cardiac care : inotropes and inodilators
Published on behalf of the European Society of Cardiology. © The Author(s) 2020..
Acute heart failure (AHF) continues to be a substantial cause of illness and death, with in-hospital and 3-month mortality rates of 5% and 10%, respectively, and 6-month re-admission rates in excess of 50% in a range of clinical trials and registry studies; the European Society of Cardiology (ESC) Heart Failure Long-Term Registry recorded a 1-year death or rehospitalization rate of 36%. As regards the short-term treatment of AHF patients, evidence was collected in the ESC Heart Failure Long-Term Registry that intravenous (i.v.) treatments are administered heterogeneously in the critical phase, with limited reference to guideline recommendations. Moreover, recent decades have been characterized by a prolonged lack of successful innovation in this field, with a plethora of clinical trials generating neutral or inconclusive findings on long-term mortality effects from a multiplicity of short-term interventions in AHF. One of the few exceptions has been the calcium sensitizer and inodilator levosimendan, introduced 20 years ago for the treatment of acutely decompensated chronic heart failure. In the present review, we will focus on the utility of this agent in the wider context of i.v. inotropic and inodilating therapies for AHF and related pathologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
European heart journal supplements : journal of the European Society of Cardiology - 22(2020), Suppl D vom: 23. Mai, Seite D3-D11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Guarracino, Fabio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute heart failure |
|---|
| Anmerkungen: |
Date Revised 23.05.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/eurheartj/suaa090 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310139910 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310139910 | ||
| 003 | DE-627 | ||
| 005 | 20231225135437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/suaa090 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310139910 | ||
| 035 | |a (NLM)32431568 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Guarracino, Fabio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Short-term treatments for acute cardiac care |b inotropes and inodilators |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Published on behalf of the European Society of Cardiology. © The Author(s) 2020. | ||
| 520 | |a Acute heart failure (AHF) continues to be a substantial cause of illness and death, with in-hospital and 3-month mortality rates of 5% and 10%, respectively, and 6-month re-admission rates in excess of 50% in a range of clinical trials and registry studies; the European Society of Cardiology (ESC) Heart Failure Long-Term Registry recorded a 1-year death or rehospitalization rate of 36%. As regards the short-term treatment of AHF patients, evidence was collected in the ESC Heart Failure Long-Term Registry that intravenous (i.v.) treatments are administered heterogeneously in the critical phase, with limited reference to guideline recommendations. Moreover, recent decades have been characterized by a prolonged lack of successful innovation in this field, with a plethora of clinical trials generating neutral or inconclusive findings on long-term mortality effects from a multiplicity of short-term interventions in AHF. One of the few exceptions has been the calcium sensitizer and inodilator levosimendan, introduced 20 years ago for the treatment of acutely decompensated chronic heart failure. In the present review, we will focus on the utility of this agent in the wider context of i.v. inotropic and inodilating therapies for AHF and related pathologies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute heart failure | |
| 650 | 4 | |a Advanced heart failure | |
| 650 | 4 | |a Cardiogenic shock | |
| 650 | 4 | |a Inodilators | |
| 650 | 4 | |a Inotropes | |
| 650 | 4 | |a Levosimendan | |
| 650 | 4 | |a Right ventricular failure | |
| 700 | 1 | |a Zima, Endre |e verfasserin |4 aut | |
| 700 | 1 | |a Pollesello, Piero |e verfasserin |4 aut | |
| 700 | 1 | |a Masip, Josep |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal supplements : journal of the European Society of Cardiology |d 1999 |g 22(2020), Suppl D vom: 23. Mai, Seite D3-D11 |w (DE-627)NLM114414629 |x 1520-765X |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2020 |g number:Suppl D |g day:23 |g month:05 |g pages:D3-D11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/eurheartj/suaa090 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2020 |e Suppl D |b 23 |c 05 |h D3-D11 | ||